Why IMU is a multi multi bagger, page-6470

Meanwhile, back in Ohio......

Prof Pravin Kaumaya must be making progress with his planned anti PD-L1 B cell vaccine.

He flagged that work as part of the OSU/Imugene partnership in his Science series presentation on 23 Feb. Check out Slides 21 and 22 of the presentation:
https://static1.squarespace.com/static/5b63d41b3e2d09b1f56bf483/t/62156d4f47397c1133df7c25/1645571463514/IMU+Science+Series+PD1-Vaxx+Feb2021.pdf

On 20 April he is scheduled to present at the World Vaccine Congress in Washington. His topic is: "Engineering a novel PD-L1 B-cell epitope vaccine and combination with HER-2 vaccine or PD-1 vaccine."

Source:
ttps://www.terrapinn.com/conference/world-vaccine-congress-washington/agenda.stm

Imugene has layer upon layer of product development in progress, with a keen focus on combination therapies. They can combine IMU products with existing commercial drugs eg in the new Her-vaxx trials, or in the extension PD1-vaxx trial with Roche's PD-L1 inhibitor drug Tecentriq. However they also have the capability to produce vaccines addressing any validated target, and combine their own products together.

Prof K is developing his own B-cell PD-L1 inhibitor, which will hopefully be as good as Tecentriq but without the toxicity/side effects. The longer term plan is a combination therapy of PD1-vaxx plus the new PD-L1 inhibitor, plus Her-vaxx (or B-vaxx) - which could be remarkable.

Cheers

Dave